Evidence map›Paper›PMID 40025450›Full record

ArticleBMC infectious diseases2025

Epidemiological profile and antimicrobial resistance trends of Staphylococcus aureus in Chinese pediatric intensive care units from 2016 to 2022: a multi-center retrospective study.

Xiao-Lei Zhang, Jing Liu, Pan Fu, Yi-Xue Wang, Pan-Pan Fan, Jin-Lan Zhou, Xian-Qi Xiang, Hui-Li Shen, Ting-Yan Liu, Ying-Ying Zhang and 6 more

Abstract readMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiao-Lei Zhang *Department of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Jing Liu *Department of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Pan Fu *Department of Clinical Laboratory, Lab of Microbiology, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Yi-Xue WangDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Pan-Pan FanDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Jin-Lan ZhouDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Xian-Qi XiangDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Hui-Li ShenDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Ting-Yan LiuDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Ying-Ying ZhangDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Ting ZhuDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Cai-Yan ZhangDepartment of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China.
Chuan-Qing Wang *Department of Clinical Laboratory, Lab of Microbiology, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China. chuanqing523@163.com.
Guo-Ping Lu *Department of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China. 13788904150@163.com.
Gang-Feng Yan *Department of Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National Center for Children's Health, 399 Wanyuan Road, Shanghai, 201102, P.R. China. gangfeng_yan@fudan.edu.cn.
China paediatric Intensive care Unit Pathogen Surveillance Network (CHIPS) Study Group

Funding

the National Key Research and Development Program of China 2021YFC2701800, 2021YFC2701805the Scientific Research Project of Shanghai Municipal Health Commission No. 202140442the Shanghai Municipal Health System major supports discipline projects 2023ZDFC0103
6 · The paper itself

Abstract

objectiveThis study aimed to analyze the profiles and evolution of Staphylococcus aureus in the pediatric intensive care units (PICUs) of 17 hospitals in China from 2016 to 2022.

methodsSusceptibility testing was performed to bacterial strains with a uniform monitoring protocol, which was provided by the US Clinical and Laboratory Standards Institute (CLSI) and used by the China Antimicrobial Surveillance Network (CHINET). The results were interpreted in accordance with the performance standards for antimicrobial susceptibility testing issued by the US Clinical and Laboratory Standards Institute.

resultsTwenty-six thousand six hundred thirteen bacterial strains were isolated from 17 PICUs in China from 2016 to 2022, 3,147 of which were Staphylococcus aureus, ranking second among etiological agents of infections from PICUs. In 2022, Staphylococcus aureus had the highest detection rate, being 36.19%. And in 2021, MRSA had the highest detection rate, being 10.35% in Staphylococcus aureus. There were statistically significant differences in the annual detection rate of gram-positive bacteria, Staphylococcus aureus and MRSA between the years from 2016 to 2022 (P < 0.05). More males were found with Staphylococcus aureus or methicillin-resistant Staphylococcus aureus, but there were no statistical differences in gender distribution between any two years (P < 0.05). The top 3 highest detection rate of Staphylococcus aureus in age groups were infants (1244, 39.7%), toddlers (741, 23.7%), and children at school age and older (731, 23.4%). For MRSA, The top 3 in age groups were infants (91, 38.9%), children at school age and older (87, 29.1%), and toddlers (48, 20.5%). The detection rate of Staphylococcus aureus was statistically different in the distribution of age stratification (P < 0.05). There was no statistically significant difference in these two aspects of MRSA (P > 0.05). The top 3 highest detection rate of Staphylococcus aureus in infected sites were the lower respiratory tract (2,552, 81.7%), bloodstream (217, 6.5%), and skin wounds (110, 3.9%). For MRSA, The top 3 in infected sites were the lower respiratory tract (156, 77.9%), skin wounds (47, 8.8%), and bloodstream (15, 6.6%). The detection rate of Staphylococcus aureus and MRSA was statistically different in the distribution of infected sites (P < 0.05). All the strains of Staphylococcus aureus were sensitive to tigecycline, nitrofurantoin, vancomycin, and linezolid. The resistant rate of Staphylococcus aureus, to penicillin G was as high as 87.5% at least, to erythromycin was as high as 51.8% at least, to benzocillin was as high as 38.0% at least, to cefoxitin was as high as 35.5% at least, and to clindamycin was as high as 32.7% at least. All the strains of MRSA were sensitive to vancomycin, linezolid, quinupristin/dalfopristin, and tigecycline. Of these 234 strains of MRSA, 179 (76.5%) were resistant to erythromycin, 116 (49.6%) to clindamycin, 39 (16.7%) to tetracycline, 29 (12.4%) to levofloxacin, 27 (11.5%) to ciprofloxacin, 27 (11.5%) to moxifloxacin, 14 (6.0%) to TMP-SMX, eight (3.4%) to rifampicin, and six (2.6%) to gentamicin.

conclusionsStaphylococcus aureus is the most common gram-positive bacterium in PICUs. Infants are most likely to be infected by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. And the lower respiratory tract is the most common infected site of Staphylococcus aureus. Staphylococcus aureus has a high resistant rates to commonly used antimicriobials in pediatrics, but no strains resistant to vancomycin and/or linezolid were found. When considering Staphylococcus aureus infection clinically, it is necessary to select antimicrobials reasonably based on the patient's age, infected site and local epidemiological characteristics.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialIntensive Care Units, PediatricStaphylococcal InfectionsStaphylococcus aureusAdolescentChildChild, PreschoolChinaEast Asian PeopleFemaleHumansInfantInfant, NewbornMaleMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsAntimicrobial resistanceEvolutionPediatric intensive-care unitStaphylococcus aureus

Identifiers

PMID40025450
PMCPMC11874852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.